Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: Evidence from the GenPheRex Study

HIV Medicine

Volumn 4, Issue 3, 2003, Pages 263-270

  Torti, Carlo ^a   Quiros Roldan, E ^a   Scudeller, L ^b,h   Lo Caputo, S ^c   Tomasoni, L ^a   Castelli, F ^a   Poggio, A ^d   Delle Foglie, P ^e,h   Chirianni, A ^f,h   Sighinolfi, L ^g   Mazzotta, F ^c   Carosi, G ^a   Toti, M ^h   Donati, E ^h   Alberici, F ^h   Sisti, M ^h   Cadeo, G ^h   Vangi, D ^h   Loiacono, A ^h   Lazzarin, A ^h   Gianotti, N ^h   Leoncini, F ^h   Pozzi, M ^h   Vullo, V ^h   Pastore, G ^h   Ladisa, N ^h   Dionisio, D ^h   Vivarelli, A ^h   Scasso, A ^h   De Gennaro, M ^h   Resta, F ^h   Buccoliero, G ^h   Ghinelli, F ^h   Angarano, G ^h   Tinelli, C ^h   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d Ospedale   (Italy)

^e SANTA CHIARA HOSPITAL   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g S ANNA HOSPITAL   (Italy)

^h NONE

Author keywords

Highly active antiretroviral therapy; HIV; Immunologic recovery

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; GENOTYPE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LINEAR REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHENOTYPE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD;

EID: 84988222656     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00154.x     Document Type: Article

References (21)

1. Piketty C, Weiss L, Thomas F, Mohamed A, Belec L, Kazatchkine M. Long-term clinical outcome of HIV-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183: 1328-1335.
2. Le Moing V, Thièbaut R, Chène G et al. Predictors of long-term increase in CD4 cell counts in HIV-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185: 471-480.
3. Deeks S, Martin J. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. AIDS 2001; 15: 117-119.
4. Sieg S, Mitchem J, Bazar D, Lederman M. Close link between CD4 and CD8 T cell proliferation defects in patients with HIV disease and relationship to extended periods of CD4 lymphopenia. J Infect Dis 2002; 185: 1401-1408.
5. Deeks S, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-480.
6. Phenix B, Qangel J, Mandy F et al. Decreased HIV-associated T cell apoptosis by HIV proteases inhibitors. AIDS Res Hum Retroviruses 2000; 16: 559-567.
7. Deeks S, Barbour JD, Martin J, Swanson M, Grant R. Sustained CD4 T cell response after virologic failure of protease inhibitor-based regimens in patients with HIV infection. J Infect Dis 2000; 181: 946-953.
8. Mazzotta F, Lo Caputo S, Torti C et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003; 32: 268-280.
9. Harrigan PR, Montaner JSG, Wegner SA et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15: 1671-1677.
10. D'Aquila RT, Schapiro JM, Brun-Vezinet F et al. Drug resistance mutations in HIV-1. IAS-USA Web site. http://www.iausa.org.htm 2002
11. Tortajada C, Garcia F, Plana M et al. Comparison of T-cell subsets' reconstitution after 12 months of HAART initiated during early versus advanced states of HIV disease. J Acquir Immune Defic Syndr 2000; 25: 296-2567.
12. Kaufmann G, Bloch M, Zaunders J et al. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-969.
13. Yeni P, Hammer S, Carpenter C et al. Antiretroviral treatment for adult HIV infection in 2002. JAMA 2002; 288: 222-235.
14. Antinori A, Liuzzi G, Cingolani A et al. Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy. AIDS 2001; 15: 2325-2327.
15. The AVANTI & INCAS Study Groups. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. AIDS 2000; 14: 1383-1388.
16. Wood E, Hogg RS, Yip B et al. 'Discordant' increases in CD4 + cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 159-166.
17. Phenix B, Lum J, Nie Z, Sanchez-Daedon J, Badley A. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001; 98: 1078-1085.
18. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-1873.
19. Plana M, Martinez C, Garcia F et al. Immunologic reconstitution after 1 year of highly active antiretroviral therapy with or without protease inhibitors. J Acquir Immune Defic Syndr 2002; 29: 429-434.
20. Barreiro P, Soriano V, Casas E et al. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002; 16: 245-249.
21. Deeks SG, Martin JN, Hoh R, Wrin T, Petropoulos C, Grant RM. Continued reverse transcriptase inhibitor therapy is sufficient to maintain short-term partial suppression of multi-drug resistant viremia [abstract 640]. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2003 [Abstract 640].